Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Epigenetic Priming By Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-Cell Lymphoma

George Ward, Zhiqiang Zhang, Simone Jueliger, Ilya Potapov, Matthew P Davis, Adam Boxall, Jason A Taylor, Harold N. Keer, Andrea Biondo, John F Lyons, Martin Sims, Tomoko Smyth

Blood (2023) 142 (Supplement 1): 1439.

https://doi.org/10.1182/blood-2023-186712

Published: 2023

Journal Articles

ASTX660-01 Phase 2: A Case Study of Tolinapant-Induced Pseudoprogression in CTCL

Brian Poligone, Simone Jueliger, Matthew P Davis, Ilya Potapov, George Ward, Tomoko Smyth, Jason A Taylor, Harold N. Keer, Martin Sims

Blood (2023) 142 (Supplement 1): 6205.

https://doi.org/10.1182/blood-2023-179195

Published: 2023

Journal Articles

Phase 2 Study of Oral Decitabine/Cedazuridine in Combination with Magrolimab for Previously Untreated Subjects with Intermediate to Very High-Risk Myelodysplastic Syndromes (MDS)

Amer M. Zeidan, Karen Mosher, Sonia Souza, Beloo Mirakhur, Harold N. Keer, Jason A. Taylor

Blood (2022) 140 (Supplement 1): 9779–9780.

https://doi.org/10.1182/blood-2022-158276

Published: 2022

Journal Articles

Tolinapant, a Non-Peptidomimetic Antagonist of Inhibitors of Apoptosis Proteins, cIAP1/2 and XIAP, in Combination with the Hypomethylating Agents, Azacytidine and Decitabine Are Highly Synergistic in in Vitro Models of T Cell Lymphoma

John Sanil Manavalan, Ipsita Pal, Aidan Pursley, George A. Ward, Tomoko Smyth, Martin Sims, Jason A. Taylor, David J Feith, Thomas P. Loughran, Jr., Owen A. O'Connor, Enrica Marchi

Blood (2022) 140 (Supplement 1): 11552–11553.

https://doi.org/10.1182/blood-2022-169906

Published: 2022

Journal Articles

A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma

Jake Shortt, Brian Poligone, Vincent Ribrag, Pier Luigi Zinzani, Dima El-Sharkawi, Jan Walewski, Anca Prica, Laksmi Wilson, Sonia Souza, Harold N. Keer, Jason A. Taylor, Enrica Marchi

Blood (2022) 140 (Supplement 1): 12033–12034.

https://doi.org/10.1182/blood-2022-158650

Published: 2022

Journal Articles

Combining the IAP Antagonist Tolinapant with a DNA Hypomethylating Agent Enhances Immunogenic Cell Death in Preclinical Models of T-Cell Lymphoma

George A. Ward, Simone Jueliger, Martin Sims, Matthew Davis, Adam Boxall, Harpreet Saini, Jason A. Taylor, Andrea Biondo, John F. Lyons, Tomoko Smyth

Blood (2021) 138 (Supplement 1): 3986.

https://doi.org/10.1182/blood-2021-152176

Published: 2021

Journal Articles

Thrombin: A Driver or Attenuator of Bone Disease on Hemophilia?

Galen Goldscheitter, BS, BA, Robert Klein, MD, Jason A Taylor, MD PhD

Blood (2019) 134 (Supplement_1): 4916.

https://doi.org/10.1182/blood-2019-130698

Published: 2019

Journal Articles

The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden

Srdan Verstovsek, MD PhD, Bart L. Scott, MD, Jason A Taylor, MD PhD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 1674.

https://doi.org/10.1182/blood-2019-127609

Published: 2019

Journal Articles

Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib

Jennifer O'Sullivan, MD, Jason A Taylor, MD PhD, Aaron T. Gerds, MD MS, Sarah A Buckley, MD, Claire N Harrison, Professor, Stephen T. Oh, MD, Kieran Howard, Helene Marie-Pierre Dreau, PhD, Angela Hamblin, MD PhD, Adam J. Mead, MD PhD

Blood (2019) 134 (Supplement_1): 4214.

https://doi.org/10.1182/blood-2019-129254

Published: 2019

Journal Articles

Decreased Skeletal Health Negatively Impacts Quality of Life of People with Hemophilia

Galen Goldscheitter, BS, BA, Susan Lattimore, Jason A Taylor, MD PhD

Blood (2018) 132 (Supplement 1): 1207.

https://doi.org/10.1182/blood-2018-99-113086

Published: 2018

Journal Articles

The Role of Thrombin Deficiency on Skeletal Health

Hillary J Taylor, BS, Galen Goldscheitter, BS, BA, Jason A Taylor, MD PhD

Blood (2018) 132 (Supplement 1): 5012.

https://doi.org/10.1182/blood-2018-99-118989

Published: 2018

Journal Articles

Factor VIII Plays a Direct Role in Osteoblast Development

Emily Ann Larson, BS, Jason A Taylor, MD PhD

Blood (2017) 130 (Supplement 1): 3661.

https://doi.org/10.1182/blood.V130.Suppl_1.3661.3661

Published: 2017

Journal Articles

Decreased In Vitro Osteoblast Mineralization in Primary Bone Marrow Stromal Cells (MSCs) Derived from FVIII-Deficient Mice

Emily A Larson, Jason A Taylor, MD PhD

Blood (2016) 128 (22): 560.

https://doi.org/10.1182/blood.V128.22.560.560

Published: 2016

Journal Articles

Factor XIII Contributes to Clot Formation and Thrombin Generation

M Rick Rollins, Emily A Larson, Hillary J Larson, Jason A Taylor, MD PhD

Blood (2016) 128 (22): 208.

https://doi.org/10.1182/blood.V128.22.208.208

Published: 2016

Journal Articles

Factor IX-Deficient Mice Have Decreased Skeletal Health

Emily A Larson, Jason A Taylor, MD PhD

Blood (2016) 128 (22): 559.

https://doi.org/10.1182/blood.V128.22.559.559

Published: 2016

Journal Articles

Time to Abandon the Serum Cobalamin Level for Diagnosing Vitamin B12 Deficiency

Sven R Olson, MD, Thomas G. Deloughery, MD, Jason A Taylor, MD PhD

Blood (2016) 128 (22): 2447.

https://doi.org/10.1182/blood.V128.22.2447.2447

Published: 2016

Journal Articles

A new era for hemophilia B treatment

Jason A. Taylor, Rebecca Kruse-Jarres

Blood (2016) 127 (14): 1734–1736.

https://doi.org/10.1182/blood-2016-02-694869

Published: 2016

Journal Articles

The Clinical Associations and Outcomes of Patients Admitted with Acquired Hemophilia; A Review of the 2012 National Inpatient Sample

Joseph Shatzel, MD, Sharl Azar, MD, Nathanael David Gay, MD, Jai Luo, MD, Thomas G. Deloughery, MD, Michael Recht, MD PhD, Jason A. Taylor, MD PhD

Blood (2015) 126 (23): 1091.

https://doi.org/10.1182/blood.V126.23.1091.1091

Published: 2015

Journal Articles

Age-Associated Bone Disease in Factor VIII-Deficient Mice

Emily A. Larson, Urszula T. Iwaniec, PhD, Sigrid C. Holmgren, MS, Russell T. Turner, PhD, Michael Recht, MD PhD, Jason A. Taylor, MD PhD

Blood (2014) 124 (21): 2798.

https://doi.org/10.1182/blood.V124.21.2798.2798

Published: 2014

Journal Articles

Biomarkers Of Bone Disease In Subjects With Hemophilia

Michael Recht, MD, PhD, Percell Carly, Emily Larson, Marilyn J. Manco-Johnson, MD, Jason A. Taylor, MD, PhD

Blood (2013) 122 (21): 1113.

https://doi.org/10.1182/blood.V122.21.1113.1113

Published: 2013

NARROW

Epigenetic Priming By Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-Cell Lymphoma

ASTX660-01 Phase 2: A Case Study of Tolinapant-Induced Pseudoprogression in CTCL

Phase 2 Study of Oral Decitabine/Cedazuridine in Combination with Magrolimab for Previously Untreated Subjects with Intermediate to Very High-Risk Myelodysplastic Syndromes (MDS)

Tolinapant, a Non-Peptidomimetic Antagonist of Inhibitors of Apoptosis Proteins, cIAP1/2 and XIAP, in Combination with the Hypomethylating Agents, Azacytidine and Decitabine Are Highly Synergistic in in Vitro Models of T Cell Lymphoma

A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma

Combining the IAP Antagonist Tolinapant with a DNA Hypomethylating Agent Enhances Immunogenic Cell Death in Preclinical Models of T-Cell Lymphoma

Thrombin: A Driver or Attenuator of Bone Disease on Hemophilia?

The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden

Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib

Decreased Skeletal Health Negatively Impacts Quality of Life of People with Hemophilia

The Role of Thrombin Deficiency on Skeletal Health

Factor VIII Plays a Direct Role in Osteoblast Development

Decreased In Vitro Osteoblast Mineralization in Primary Bone Marrow Stromal Cells (MSCs) Derived from FVIII-Deficient Mice

Factor XIII Contributes to Clot Formation and Thrombin Generation

Factor IX-Deficient Mice Have Decreased Skeletal Health

Time to Abandon the Serum Cobalamin Level for Diagnosing Vitamin B12 Deficiency

A new era for hemophilia B treatment

The Clinical Associations and Outcomes of Patients Admitted with Acquired Hemophilia; A Review of the 2012 National Inpatient Sample

Age-Associated Bone Disease in Factor VIII-Deficient Mice

Biomarkers Of Bone Disease In Subjects With Hemophilia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only